The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non–iron-related chronic liver disease
Open accessAbstract
It has been suggested that excess iron may facilitate the occurrence of cancer. Patients with hereditary hemochromatosis (HH) are at high risk of developing liver cancer, and studies of limited series reported a high frequency of nonhepatic cancers. To verify whether patients with HH are at higher risk of liver cancer and other malignancies as compared with patients with non-iron-related chronic liver disease (CLD), we analyzed the occurrence of neoplasms in 230 patients with HH and 230 with non-iron-related CLD. The patients were matched by sex, age, duration of follow-up (+/-5 years), and severity of liver disease. On enrollment, the following variables were considered: hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, alcohol abuse, smoking, and a family history of cancer (first-degree relatives). The diagnosis of primary cancers was confirmed by histology. During the follow-up, hepatocellular carcinoma (HCC) developed in 49 and 29 patients (all cirrhotic patients) with HH and non-iron-related CLD, respectively, with a relative risk of 1.8 (95% confidence interval [CI] 1.1-2.9); nonhepatic cancers occurred in 20 and 11 patients, respectively, with a relative risk of 1.8 (95% CI 0.8-4). Four patients with HH and 1 with non-iron-related CLD developed 2 different primary cancers during follow-up. The risk of cancer after adjustment for alcohol abuse, smoking, and family history of cancer was 1.9 (95% CI 1.1-3.1) in the patients with HH. In conclusion, patients with HH are at high risk of both liver cancer and other malignancies, which should be carefully sought during follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
Feder, J. N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D. A., Basava, A., Dormishian, F., Domingo, R., Ellis, M. C., Fullan, A., et al. (1996) · Nature Genetics · doi:10.1038/ng0896-399 · Cited by 3,664
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
Iron and cancer: more ore to be mined
Torti, S. V., & Torti, F. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3495 · Cited by 1,621
Epidemiology and surveillance for hepatocellular carcinoma: New trends
Singal, A. G., Lampertico, P., & Nahon, P. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.025 · Cited by 1,102
Martin, P., DiMartini, A., Feng, S., Brown, R., & Fallon, M. (2014) · Hepatology · doi:10.1002/hep.26972 · Cited by 1,045
“The risk of HCC in cirrhosis due to hereditary hemochromatosis appears to be greater than in other causes of cirrhosis.(168) Although elevated iron studies may be seen in patients with other causes of liver disease, particularly alcohol, NAFLD, and HCV, coexisting hereditary hemochromatosis is uncommon.”
BackgroundHepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification
(2021) · Advances in Cancer Research · doi:10.1016/bs.acr.2020.10.001 · Cited by 851
Cancer Treatment through Nanoparticle-Facilitated Fenton Reaction
Ranji-Burachaloo, H., Gurr, P. A., Dunstan, D. E., & Qiao, G. G. (2018) · ACS Nano · doi:10.1021/acsnano.8b07635 · Cited by 559
Overview of iron metabolism in health and disease
Dev, S., & Babitt, J. L. (2017) · Hemodialysis International · doi:10.1111/hdi.12542 · Cited by 462
Iron, hemochromatosis, and hepatocellular carcinoma
Kowdley, K. V. (2004) · Gastroenterology · doi:10.1016/j.gastro.2004.09.019 · Cited by 391
Iron and Cancer Risk—A Systematic Review and Meta-analysis of the Epidemiological Evidence
Fonseca-Nunes, A., Jakszyn, P., & Agudo, A. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0733 · Cited by 350
Population attributable fractions of risk factors for hepatocellular carcinoma in the United States
Makarova‐Rusher, O. V., Altekruse, S. F., McNeel, T. S., Ulahannan, S., Duffy, A. G., Graubard, B. I., Greten, T. F., & McGlynn, K. A. (2016) · Cancer · doi:10.1002/cncr.29971 · Cited by 332
Treatment predictors of a sustained virologic response in hepatitis B and C
Kau, A., Vermehren, J., & Sarrazin, C. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.07.013 · Cited by 324
Iron and immunity: a double-edged sword.
Weiss, G. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2002.0320s1070.x · Cited by 317
Eid, R., Arab, N. T. T., & Greenwood, M. T. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.12.002 · Cited by 288
Subramaniam, A., Shanmugam, M. K., Perumal, E., Li, F., Nachiyappan, A., Dai, X., Swamy, S. N., Ahn, K. S., Kumar, A. P., Tan, B. K. H., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.10.002 · Cited by 278
Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives
Elmberg, M., Hultcrantz, R., Ekbom, A., Brandt, L., Olsson, S., Olsson, R., Lindgren, S., Lööf, L., Stål, P., Wallerstedt, S., et al. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.035 · Cited by 273
ACG Clinical Guideline: Hereditary Hemochromatosis
Kowdley, K. V., Brown, K. E., Ahn, J., & Sundaram, V. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000315 · Cited by 272
Review article: the iron overload syndromes
Siddique, A., & Kowdley, K. V. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05051.x · Cited by 162
“than in comparable cirrhosis due to other chronic liver disease.(145) The risk of HCC is further increased in the presence of other co-factors, such as alcohol abuse, viral hepatitis and age over 55 years.”
BackgroundIron storage disease: Facts, fiction and progress
Beutler, E. (2007) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2007.03.009 · Cited by 101
Asare, G. A., Mossanda, K. S., Kew, M. C., Paterson, A. C., Kahler-Venter, C. P., & Siziba, K. (2006) · Toxicology · doi:10.1016/j.tox.2005.11.006 · Cited by 98
Metadata
- Authors
- Fracanzani, A.
- Venue
- Hepatology
- Published
- 2001-03
- Volume
- 33
- Issue
- 3
- Pages
- 647-651
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2074705008
- Cited by
- 245
- References
- 1
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.